Helle Sorensen, Communications Officer
LEoPARDS results published. A trial published last week in the New England Journal of Medicine shows that adding levosimendan to standard care did not reduce organ dysfunction or mortality in adult patients with septic shock.
LeoPARDS (The Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis) was designed to test whether levosimendan, when added to standard treatment, could reduce organ dysfunction in septic shock. It recruited patients from 34 ICUs in the UK.
The trial found that patients treated with levosimendan required more norepinephrine, were less likely to be successfully extubated, and had more tachycardia and a higher rate of supra-ventricular arrhythmias.
National Institute for Health Research (NIHR) Research Professor Anthony Gordon and a Director of Research for the Intensive Care Society conducted the trial. The trial was supported by the Intensive Care Foundation.
See also the results of the Intensive Care Foundation supported VANISH trial, recently published in JAMA, which found that vasopressin can be used as an alternative to the commonly used adrenaline-like drugs to improve blood pressure in septic shock.